Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies.

Hegde UP, Mukherji B.

Cancer Immunol Immunother. 2017 Sep;66(9):1113-1121. doi: 10.1007/s00262-017-2007-x. Epub 2017 May 11. Review.

2.

Randomized double-blind placebo-controlled trial of celecoxib for oral mucositis in patients receiving radiation therapy for head and neck cancer.

Lalla RV, Choquette LE, Curley KF, Dowsett RJ, Feinn RS, Hegde UP, Pilbeam CC, Salner AL, Sonis ST, Peterson DE.

Oral Oncol. 2014 Nov;50(11):1098-103. doi: 10.1016/j.oraloncology.2014.08.001. Epub 2014 Aug 21.

3.

Metastatic melanoma in the older patient: special considerations.

Hegde UP, Grant-Kels JM.

Clin Dermatol. 2013 May-Jun;31(3):311-6. doi: 10.1016/j.clindermatol.2012.08.011. Review.

PMID:
23608450
4.

Analyses of T cell-mediated immune response to a human melanoma-associated antigen by the young and the elderly.

Chakraborty NG, Yadav M, Dadras SS, Singh P, Chhabra A, Feinn R, Kerr PE, Grant-Kels JM, Mukherji B, Hegde UP.

Hum Immunol. 2013 May;74(5):640-7. doi: 10.1016/j.humimm.2013.01.015. Epub 2013 Feb 4.

PMID:
23391568
5.

Ethical issues in cutaneous melanoma.

Hegde UP, Grant-Kels JM.

Clin Dermatol. 2012 Sep-Oct;30(5):501-10. doi: 10.1016/j.clindermatol.2011.06.020.

PMID:
22902221
6.

Metastatic melanoma in the older patient: immunologic insights and treatment outcomes.

Hegde UP, Chakraborty N, Mukherji B, Grant Kels JM.

Expert Rev Pharmacoecon Outcomes Res. 2011 Apr;11(2):185-93. doi: 10.1586/erp.11.14. Review.

PMID:
21476820
7.

Intrathoracic lymphadenopathy: sarcoidosis or metastatic seminoma? The diagnostic dilemma revisited.

Trikudanathan G, Philip A, Hegde UP.

Conn Med. 2010 Aug;74(7):403-6.

PMID:
20806619
8.

Melanoma in the elderly patient: relevance of the aging immune system.

Hegde UP, Chakraborty N, Kerr P, Grant-Kels JM.

Clin Dermatol. 2009 Nov-Dec;27(6):537-44. doi: 10.1016/j.clindermatol.2008.09.012. Review.

PMID:
19880041
9.

Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia.

Hegde UP, Wilson WH, White T, Cheson BD.

Blood. 2002 Sep 15;100(6):2260-2. Review.

10.

The effects of 13-cis retinoic acid and interferon-alpha in chronic myelogenous leukemia cells in vivo in patients.

Handa H, Hegde UP, Kotelnikov VM, Mundle SD, Dong LM, Burke P, Rose S, Hsu WT, Gaskin F, Raza A, Preisler HD.

Leuk Res. 1997 Nov-Dec;21(11-12):1087-96.

PMID:
9444943
11.

Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase.

Handa H, Hegde UP, Kotelnikov VM, Mundle SD, Dong LM, Burke P, Rose S, Gaskin F, Raza A, Preisler HD.

Leuk Res. 1997 Jun;21(6):479-89.

PMID:
9279359
12.

Prognostic significance of myeloperoxidase containing blast cells in acute myelogenous leukaemia.

Advani SH, Hegde UP, Iyer RS, Gopal R, Saikia TK, Pai SK, Nair CN, Kurkure PA, Pai VR, Nadkarni KS.

Indian J Med Res. 1993 Feb;98:8-14.

PMID:
8388366
13.

Chronic myeloid leukemia following radioactive iodine (131)I therapy of thyroid cancer.

Hegde UP, Gopal R, Nanjangud G, Advani SH.

Leuk Lymphoma. 1991;5(2-3):215-7. doi: 10.3109/10428199109068129.

PMID:
21269085

Supplemental Content

Loading ...
Support Center